Celldex Therapeutics, Inc. — Net Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/916d8a50-eca5-47b4-b248-edb83c16c5e4/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-258.8M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-019652 |
| FY 2024 | $-157.9M | 2024-01-01 – 2024-12-31 | evidence 0001104659-26-019652 |
| FY 2023 | $-141.4M | 2023-01-01 – 2023-12-31 | evidence 0001104659-26-019652 |
| FY 2022 | $-112.3M | 2022-01-01 – 2022-12-31 | evidence 0001104659-26-050884 |
| FY 2021 | $-70.5M | 2021-01-01 – 2021-12-31 | evidence 0001104659-26-050884 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Celldex Therapeutics, Inc. — all facts · Revenue · Operating Income